The landscape of geographic atrophy (GA) treatment has undergone a paradigm shift following the FDA approval of complement inhibitors. However, recent clinical findings presented at the American Society of Retina Specialists (ASRS) meeting in Montreal have introduced a significant layer of uncertainty. According to a new study, patients receiving complement inhibitor therapies for GA are experiencing a consistent thickening of the retinal nerve fiber layer (RNFL), a physiological change that experts fear could either represent a novel neuroprotective mechanism or a burgeoning, potentially pathologic, complication.
The Core Findings: A Deviation from Natural History
The investigation, led by David Brown, MD, of Retina Consultants of Texas, examined the longitudinal effects of intravitreal injections on ocular anatomy. The study compared 331 eyes suffering from age-related macular degeneration (AMD) across various treatment groups, utilizing 4,870 optical coherence tomography (OCT) measurements to track shifts in the RNFL over several years.
The data revealed a stark contrast between standard care and the emerging class of complement inhibitors. In the control group—patients with dry AMD who received no intravitreal injections—the RNFL thickness naturally declined by an average of 0.29 µm per year. Similarly, patients treated with anti-VEGF injections, the gold standard for wet AMD, exhibited an annual RNFL reduction of 0.79 µm, a rate not statistically different from the natural history of the disease.
In contrast, the 159 eyes treated with pegcetacoplan (Syfovre) showed an average annual RNFL increase of 4.37 µm. The 43 eyes treated with avacincaptad pegol (Izervay) showed even more pronounced growth, with an average increase of 5.72 µm per year. This thickening appeared most aggressive during the first six months of treatment, reaching a peak rate of 9.1 µm per year, before stabilizing to a persistent increase of 3.2–3.6 µm annually.
Chronology of the Research and Clinical Observation
The impetus for this research began not in a laboratory, but in the clinic. Dr. Brown and his colleagues began observing sporadic cases of ischemic optic neuropathy among patients undergoing anti-complement therapy. These anecdotal observations prompted a systematic retrospective analysis to determine if the therapeutic agents themselves were inducing structural changes to the optic nerve.
The study period spanned three to five years, allowing researchers to observe that the RNFL thickening was not merely a transient inflammatory spike, but a sustained, ongoing process.
- Initial Discovery: Clinicians noted optic nerve changes in patients receiving complement inhibitors.
- Data Synthesis: The team aggregated 4,870 OCT measurements from 331 eyes to establish a comparative baseline.
- Statistical Validation: The analysis confirmed a statistically significant difference (P<0.001) in RNFL trajectory between the complement inhibitor cohort and both the anti-VEGF and natural history cohorts.
- Presentation: The findings were presented as a late-breaking abstract at the ASRS meeting, highlighting the urgent need for further investigation.
Analyzing the Mechanism: The "PEG" Hypothesis
The mechanism behind this thickening remains a subject of intense scientific debate. A primary point of concern for Dr. Brown is the role of polyethylene glycol (PEG), a common additive used to increase the half-life of intravitreal drugs.
"Polyethylene glycol is vacuolized by macrophages," Dr. Brown explained during the session. "In preclinical data, you saw it in the nerve, and it went all the way to the brain in the avacincaptad pegol data. I think you’re giving pegylated drugs that are driving macrophage vacuolization and becoming incorporated into the retina."
The hypothesis is that the immune system, specifically macrophages, is attempting to process these pegylated molecules, leading to an accumulation within the retinal tissue. This accumulation could cause a structural thickening that mimics, but does not replicate, healthy nerve fiber density.
Dr. Brown highlighted the urgency of the situation by noting that the thickening does not appear to plateau. "The scary part is that it never plateaus. What you’re doing is thickening the nerve. You’re increasing ischemic optic neuropathy. Is this neuroprotection, edema, or infiltration? If it was neuroprotection, it would go from nerve fiber loss to zero."
Supporting Data and Comparative Analysis
The study’s data provided a rare head-to-head look at how different therapeutic modalities affect the eye’s structural integrity. While both pegcetacoplan and avacincaptad pegol induced thickening, the variance in their PEG concentrations did not lead to a significant difference in the rate of thickening.
- Pegcetacoplan (Syfovre): 4.37 µm annual gain.
- Avacincaptad pegol (Izervay): 5.72 µm annual gain, despite having a ninefold lower concentration of PEG.
These findings suggest that while PEG may play a role, the broader class of complement inhibition may be the primary driver. This theory will be put to the test in upcoming clinical trials. Researchers are looking toward the development of non-pegylated inhibitors, such as ANX007, which targets C1q. Because this drug does not utilize PEGylation, its clinical trials may provide the "control" experiment needed to determine if the thickening is a byproduct of the drug’s carrier molecule or its biological effect on the complement cascade.
Official Responses and Industry Silence
As of the date of the ASRS meeting, representatives from the manufacturers of both pegcetacoplan and avacincaptad pegol had not reached out to Dr. Brown regarding his findings. Furthermore, requests for comment from industry players by medical news outlets remain largely unaddressed.
The lack of official discourse from the pharmaceutical industry is particularly concerning to clinicians who are currently managing patients. Dr. Charles Wykoff, a co-investigator on the study, voiced the apprehension felt by many in the field: "Clinically, is this changing what you’re doing when you manage patients with anti-complement therapeutics?"
Dr. Brown’s current advice to his peers is one of cautious transparency. "I don’t know what to tell patients now. I think you’ve got to tell them. I think you’ve got to watch the RNFL. You’ve got to watch the optic nerve."
Clinical Implications and Future Directions
The implications of this study are profound, potentially forcing a rewrite of how retina specialists monitor GA patients. If the RNFL thickening is, in fact, an accumulation of foreign material or pathological edema, it could have long-term consequences for visual acuity and optic nerve health.
The Question of "Healthy" Thickening
Some researchers have posited that the thickening could be a neuroprotective response—a way of "padding" the nerve against the degenerative processes of AMD. However, Dr. Brown is skeptical. He argues that if the drug were truly neuroprotective, the result should be the stabilization of the RNFL, not a continuous, cumulative increase in thickness.
Expanding the Research
The research team is now pivoting to investigate the ganglion cell layer (GCL). By tracking the GCL alongside the RNFL, the researchers hope to determine if the entire neural structure is being bolstered or if the RNFL is expanding in isolation due to infiltration. "If the drugs are making the eye ‘healthier,’ then thickening of the ganglion cell layer would occur in parallel with the RNFL," Brown explained. "I suspect the GCL will be unchanged and this will prove that the thickening of the axons is pathologically affected."
Broadening the Scope: Is Injection Frequency the Culprit?
The debate has also expanded to include the physical act of intravitreal injection. Dr. John Thompson raised a critical question: is the trauma of repeated injections and the fluctuations in intraocular pressure (IOP) contributing to this thickening? "When we raise the IOP and put in this 0.1 mL, is this having some sort of effect? Is it possible that we’re damaging eyes when we put in this 0.1 mL?"
Brown intends to examine this further by isolating the "noise" in the anti-VEGF injection data. Approximately 8% of patients in the anti-VEGF group showed some degree of RNFL increase, which he suspects may be related to low-level inflammation caused by the injections themselves.
Conclusion: A Call for Vigilance
For now, the medical community remains in a state of watchful waiting. The discovery of RNFL thickening in patients treated with complement inhibitors for geographic atrophy serves as a vital reminder that therapeutic innovation often comes with unforeseen clinical signals.
As the field awaits more data, the consensus among experts is clear: OCT monitoring of the optic nerve and the RNFL should become a standard part of the protocol for patients receiving complement inhibition therapy. Whether this phenomenon is a harmless side effect, a sign of successful neuroprotection, or a warning of impending nerve damage remains the single most important question in the current management of GA. Until that question is answered, clinical vigilance and transparent patient communication remain the best tools available to the modern retina specialist.
